ISIN | LU1711916616 |
---|---|
Valorennummer | 38954344 |
Bloomberg Global ID | |
Fondsname | PROTEA - Sectoral Biotech Opportunities Fund IF H CHF hedged |
Fondsanbieter |
Sectoral Asset Management Inc
1010 Sherbrooke St. West, Suite 1610 QC H3A 2R7 Montreal Canada Telefon: +1 514 849 8777 E-Mail: BusinessDevelopment@sectoral.com |
Fondsanbieter | Sectoral Asset Management Inc |
Vertreter in der Schweiz |
FundPartner Solutions (Suisse) SA Genève 75 |
Distributor(en) | |
Anlagekategorie | Aktienfonds |
EFC-Kategorie | |
Anteilskategorie | Accumulation |
Domizilland | Luxemburg |
Konditionen bei der Ausgabe | Kombination von Ausgabekommission zugunsten der Fondsleitung und Transaktionsgebühr zugunsten des Fonds |
Konditionen bei der Rücknahme | Kombination von Rücknahmekommission zugunsten der Fondsleitung und Transaktionsgebühr zugunsten des Fonds |
Investment-Strategie *** | This Sub-Fund aims to achieve capital growth in USD. While respecting the principle of risk diversification, the Sub-Fund’s assets are primarily invested in equities, equity-like transferable securities, participation certificates etc. issued by particularly innovative small, mid and large cap biotech companies worldwide which are active in the human medicine sector and depositary receipts, such as American Depositary Receipts (ADRs), Global Depositary Receipts (GDRs) and European Depositary Receipts (EDRs), referring to such securities. While no geographical restrictions apply re. specific countries or regions, the industry and therefore the Sub-Fund’s investments are centered in North America and Western Europe. |
Besonderheiten |
Aktueller Preis * | 8.85 CHF | 31.10.2024 |
---|---|---|
Vorheriger Preis * | 8.96 CHF | 30.10.2024 |
52 Wochen Hoch * | 9.43 CHF | 21.08.2024 |
52 Wochen Tief * | 7.70 CHF | 09.11.2023 |
NAV * | 8.85 CHF | 31.10.2024 |
Ausgabepreis * | 8.85 CHF | 31.10.2024 |
Rücknahmepreis * | ||
Schlusskurs * | ||
Indikativer Minimalpreis | ||
Fondsvermögen *** | 22'857'438 | |
Anteilsklassevermögen *** | 1'547'552 | |
Trading Information SIX |
YTD-Performance | -1.99% |
29.12.2023 - 31.10.2024
29.12.2023 31.10.2024 |
---|---|---|
1 Monat | -2.75% |
30.09.2024 - 31.10.2024
30.09.2024 31.10.2024 |
3 Monate | -4.74% |
31.07.2024 - 31.10.2024
31.07.2024 31.10.2024 |
6 Monate | +7.80% |
30.04.2024 - 31.10.2024
30.04.2024 31.10.2024 |
1 Jahr | +14.49% |
31.10.2023 - 31.10.2024
31.10.2023 31.10.2024 |
2 Jahre | +2.67% |
31.10.2022 - 31.10.2024
31.10.2022 31.10.2024 |
3 Jahre | -23.04% |
02.11.2021 - 31.10.2024
02.11.2021 31.10.2024 |
5 Jahre | +19.43% |
31.10.2019 - 31.10.2024
31.10.2019 31.10.2024 |
Kapitalbeteiligungsquote in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anteil am Gesamtvermögen in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Immobilienquote in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Gilead Sciences Inc | 9.90% | |
---|---|---|
Regeneron Pharmaceuticals Inc | 8.57% | |
Amgen Inc | 6.33% | |
Vertex Pharmaceuticals Inc | 6.24% | |
AstraZeneca PLC ADR | 4.63% | |
Alnylam Pharmaceuticals Inc | 4.07% | |
Biogen Inc | 3.26% | |
argenx SE ADR | 2.90% | |
Moderna Inc | 2.60% | |
Biomarin Pharmaceutical Inc | 2.43% | |
Letzte Daten-Aktualisierung | 30.09.2024 |
TER | 1.45% |
---|---|
Datum TER | 30.06.2023 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 1.10% |
Ongoing Charges *** | 1.31% |
SRRI ***
|
|
Datum SRRI *** | 30.09.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |